CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $64.27B, higher than 95% of all stocks globally
- PositionReturn on equity is 23.6%, higher than 95% of its Biotechnology peers (median -21.7%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
55.05BEUR64.27B · vs all stocks (USD)
Trailing P/E
38.64xvs Biotechnology peers
Revenue (TTM)
4.59BUSD5.36B · vs all stocks (USD)
Profit Margin
32.27%vs Biotechnology peers
Beta
-0.0400xvs all stocks
52-Week Change
58.88%vs all stocks
Market Capitalization
55.05BEUR64.27B · vs all stocks (USD)
Enterprise Value
42.95BEUR50.14B · vs all stocks (USD)
Trailing P/E
38.64xvs Biotechnology peers
Forward P/E
28.37xvs Biotechnology peers
Price to Sales (TTM)
10.27xvs Biotechnology peers
Price to Book (MRQ)
7.55xvs Biotechnology peers
Enterprise to Revenue
9.36xvs Biotechnology peers
Enterprise to EBITDA
30.84xvs Biotechnology peers
Gross Margin
90.43%vs Biotechnology peers
Profit Margin
32.27%vs Biotechnology peers
Operating Margin
31.99%vs Biotechnology peers
Return on Assets (TTM)
11.63%vs Biotechnology peers
Return on Equity (TTM)
23.64%vs Biotechnology peers
Revenue (TTM)
4.59BUSD5.36B · vs all stocks (USD)
Revenue per Share (TTM)
85.91USDUpdated Aug 21, 2026Quarterly Revenue Growth
59.30%vs Biotechnology peers
Gross Profit (TTM)
2.71BUSD3.16B · vs all stocks (USD)
EBITDA (TTM)
1.77BUSD2.07B · vs all stocks (USD)
Net Income (TTM)
1.48BUSD1.73B · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
92.20%vs Biotechnology peers
Operating Cash Flow (TTM)
841.04MUSD981.95M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
657.65MUSD767.83M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.15BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
450.67MUSDFY2025 · Dec 31, 2025Gross Profit
3.70BUSDFY2025 · Dec 31, 2025Operating Income
1.05BUSDvs all stocks (USD)
Pre-tax Income
1.28BUSDFY2025 · Dec 31, 2025Income Tax Expense
-13.43MUSDFY2025 · Dec 31, 2025Net Income
1.29BUSDFY2025 · Dec 31, 2025EBIT
1.28BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.23BUSDFY2025 · Dec 31, 2025Research & Development
1.36BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.36BUSDFY2025 · Dec 31, 2025Other Operating Expenses
-82.99MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
163.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
4.08MUSDFY2025 · Dec 31, 2025EPS (Basic)
21.08USDFY2025 · Dec 31, 2025EPS (Diluted)
19.57USDFY2025 · Dec 31, 2025Basic Shares Outstanding
61.30MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
61.30MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.05BUSDFY2025 · Dec 31, 2025Operating Cash Flow
468.82MUSDFY2025 · Dec 31, 2025Free Cash Flow
462.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.49BUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.05BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
28.10MUSDFY2025 · Dec 31, 2025Stock-based Compensation
248.08MUSDFY2025 · Dec 31, 2025Other Non-cash Items
31.63MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-802.33MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-90.47MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.17MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-105.52MUSDFY2025 · Dec 31, 2025Net Acquisitions
-6.50MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.45BUSDFY2025 · Dec 31, 2025Sale of Investments
2.39BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
926.85MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-4.11MUSDFY2025 · Dec 31, 2025Other Financing Charges
-41.26MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-45.37MUSDFY2025 · Dec 31, 2025Shares Outstanding
62.54MSharesUpdated Aug 21, 2026Float Shares
62.43MSharesUpdated Aug 21, 2026% Held by Insiders
0.02%vs all stocks
% Held by Institutions
48.02%vs all stocks
Total Cash (MRQ)
4.48BUSD5.23B · vs all stocks (USD)
Total Cash per Share (MRQ)
82.89USDUpdated Aug 21, 2026Total Debt (MRQ)
40.58MUSD47.37M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0056xvs Biotechnology peers
Current Ratio (MRQ)
5.12xvs Biotechnology peers
Book Value per Share (MRQ)
116.29USDUpdated Aug 21, 2026Total Assets
8.68BUSDvs all stocks (USD)
Total Current Assets
6.90BUSDFY2025 · Dec 31, 2025Total Liabilities
1.36BUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.78BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
39.42MUSDFY2025 · Dec 31, 2025Total Current Liabilities
1.32BUSDFY2025 · Dec 31, 2025Cash
950.18MUSDFY2025 · Dec 31, 2025Cash Equivalents
2.54BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.49BUSDFY2025 · Dec 31, 2025Other Short-term Investments
948.75MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.49BUSDFY2025 · Dec 31, 2025Inventory
473.53MUSDFY2025 · Dec 31, 2025Accounts Payable
554.27MUSDFY2025 · Dec 31, 2025Short-term Debt
10.83MUSDFY2025 · Dec 31, 2025Long-term Debt
36.33MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.35MUSDFY2025 · Dec 31, 2025Retained Earnings
-279.77MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
7.32BUSDvs all stocks (USD)
52-Week Low
564.20EURUpdated Aug 21, 202652-Week High
900.60EURUpdated Aug 21, 202652-Week Change
58.88%vs all stocks
Beta
-0.0400xvs all stocks
50-Day MA
775.81EURUpdated Aug 21, 2026200-Day MA
719.15EURUpdated Aug 21, 2026Avg 10-Day Volume
80.44KSharesUpdated Aug 21, 2026Avg 30-Day Volume
84.55KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
22.71USDUpdated Aug 21, 2026Other Income / Expense
64.98MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 23.6%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.24Industry median: -0.22Industry P95: 0.23Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.80
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $64.27B, higher than 95% of all stocks globallySignificant
Market cap (USD): 64,271,460,553.713Global P95: 25,614,208,870.135
Revenue is $5.36B, above the global median of $520.53MNotable
Revenue (USD): 5,357,783,294.791Global Median: 520,528,949.311
Levered free cash flow is $767.83M, above the global median of $16.24MNotable
Levered free cash flow (USD): 767,833,186.545Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Beigene Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Boston Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Merck KGaA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regeneron Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bayer AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
UCB SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Siemens Healthineers AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samsung Biologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Edwards Lifesciences Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sk Biopharmaceuticals Co., Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Keeper Technical Laboratory
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Kalekim Kimyevi Maddeler Sanayi ve Ticaret A.Ş.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated